Li Xiao Yuan
Li Xiao Yuan — Associate Chief Physician — Medical Oncology — Peking Union Medical College Hospital
Specialties
Specializes in the medical diagnosis and treatment within comprehensive treatment systems for various solid tumors, providing full-process, standardized, optimized, and precise formulation and management of systemic chemotherapy, targeted therapy, and immunotherapy for common tumors such as lung cancer, esophageal cancer, gastric cancer, intestinal cancer, pancreatic cancer, breast cancer, head and neck tumors, and genitourinary system tumors (such as prostate cancer, urothelial carcinoma, and renal cancer); has extensive experience in diagnosing and treating rare mutation tumors and rare tumors including gastrointestinal stromal tumors and adrenocortical carcinoma. Emphasizes rehabilitation and palliative care for advanced cancer, including cancer pain management, psychological support, nutrition support, and guiding cancer survivors toward long-term healthy living.
Education
Graduated as an in-service postgraduate from Peking Union Medical College, obtaining a Master's degree in Clinical Medicine.
Professional Experience
Department of Medical Oncology, Peking Union Medical College Hospital, qualified as an associate chief physician by the National Health Commission. Entered the specialty of medical oncology in 2004 and has been working in this field since then, actively engaged in medical treatment, teaching, and research, with comprehensive knowledge of medical oncology and the latest research progress. Designated physician for charitable assistance programs for Sunitinib and Erlotinib for renal cancer. Participates in continuing education and academic exchanges in oncology, and has taken part in multiple international and domestic Phase I to IV drug clinical trials.
Professional Roles
Member of the Rare Mutations and Rare Tumors Committee of the Chinese Anti-Cancer Association, member of the Chronic Disease Management Subcommittee for Urological Tumors of the Chinese Association of Geriatric Health Care, member of the Chemotherapy Group of the Pulmonary Tumor Committee of the Chinese Medical Education Association, young member of the Neoadjuvant Therapy Committee for Rectal Cancer of the Beijing Cancer Prevention and Treatment Society, member of the MDT Diagnosis and Treatment Group for Urological and Male Reproductive System Tumors of the Beijing Urological Association, and member of the Cancer Rehabilitation and Palliative Care Committee of the Beijing Anti-Cancer Association. He is a member of the Digestive Tract Tumor MDT Expert Group, the Urological Tumor MDT Expert Group, the Brain Metastasis Difficult Cases MDT Expert Group, and the Skin Cancer and Melanoma MDT Expert Group at Peking Union Medical College Hospital.